Summary Statement. Ischaemic preconditioning protected skeletal myotubes against the effects of ischaemia-reperfusion in vitro. This protection was associated with increased Nrf2 signalling. Introduction. Ischaemic preconditioning (IPC) is a well recognised and powerful phenomenon where a tissue becomes more tolerant to a period of prolonged ischaemia when it is first subjected to short bursts of ischaemia/reperfusion. While much is known about the ability of ischaemic preconditioning to protect myocardial tissue against ischaemia-reperfusion injury, its potential to confer benefit in an orthopaedic setting by protecting skeletal muscle remains relatively unexplored to date. One mechanism by which ischaemic preconditioning may induce protection is through a reduction in oxidative stress. Reactive oxygen species (ROS) are generated both during prolonged ischaemia and also upon reperfusion by infiltrating neutrophils, thereby leading to an increase in oxidative stress. The transcription factor, NF-E2-related factor 2 (Nrf2), is a key regulator of the cells response to oxidative stress as it regulates the expression of a network of anti-oxidant/detoxifying enzymes. Nrf2 signalling has recently been shown to protect against ischaemia-reperfusion injury in both a kidney cell line and in liver biopsies, indicating that this transcription factor may play a key role in the protection provided by ischaemic preconditioning. To date, the involvement of Nrf2 in the response of skeletal muscle to ischaemia-reperfusion has not been investigated. Thus, the aims of this study were to investigate the ability of ischaemic preconditioning to protect skeletal myotubes against ischaemia-reperfusion and to determine the role of Nrf2 signalling in this protection. Materials & Methods. C2C12 mouse myoblasts were maintained at 37. o. C in a humidified atmosphere of 95% air and 5% CO. 2. in DMEM containing 20% FBS. When cultures were approximately 90% confluent, myoblasts were differentiated to myotubes by changing to DMEM supplemented with 2% horse serum and culturing for 7–10 days. Differentiated myotubes were then exposed to simulated ischaemia for 4h (1% O. 2. ) followed by 2h reoxygenation (21% O. 2. ). To precondition myotubes, cells were subjected to 30 min of simulated ischaemia followed by 1 hour reoxygenation prior to the prolonged ischaemic event. Cell survival was assessed by lactate dehydrogenase release. Changes in Nrf2 expression were assessed using real-time PCR, Western blotting and immunofluorescence. Changes in sequestosome-1 (SQSTM1), catalase (CAT), glutathione S-transferase theta-1 (GSTT1), heme oxygenase-1 (HO-1) expression were assessed using a combination of real-time PCR and Western blotting. Results. Preconditioned myotubes showed greater viability both after 4h of ischaemia, and after 4h ischaemia followed by 2h of reoxygenation. This increase in cell viability was associated with increased Nrf2 expression. In addition, increased expression of SQSTM1, and the antioxidant enzymes, CAT, GSTT1 and HO-1 was observed in preconditioned myotubes. Discussion. Our findings indicate that ischaemic preconditioning can protect skeletal myotubes against the effects of ischaemia-reperfusion in vitro. This protection is associated with increased Nrf2 signalling indicating that this transcription factor may play a role in mediating the protection induced by ischaemic preconditioning. By modulating the response of skeletal muscle to ischaemia, ischaemic preconditioning has the potential to limit reperfusion injury, which in turn, may lead to improvements in outcome following orthopaedic surgery

Ischaemia-reperfusion injury (IRI) is caused by endothelial and subendothelial damage by neutrophil-derived oxidants. Vitamin C is an antioxidant which attenuates endothelial injury after IRI. Our aim was to evaluate the effect of oral vitamin C in the prevention of IRI in skeletal muscle. We used a model of cross-clamping (3 hours) and reperfusion (1 hour) of the cremaster muscle in rats. Muscle function was assessed electrophysiologically by electrical field stimulation. Infiltration by neutrophils was determined by the activity of tissue myeloperoxidase (MPO) and tissue oedema by the wet-to-dry ratio. Neutrophil respiratory burst activity was measured in control animals and groups pretreated with vitamin C. IRI significantly decreased muscle function and increased muscle neutrophil MPO activity and muscle oedema. Pretreatment with vitamin C preserved muscle function and reduced tissue oedema and neutrophil infiltration. Neutrophil respiratory burst activity was reduced in the group treated with vitamin C compared with the control group. We conclude that pretreatment with oral vitamin C protects against acute muscle IRI, possibly by attenuating neutrophil respiratory burst activity

Introduction. Ischaemic preconditioning (IPC) is a phenomenon whereby a tissue is more tolerant to an insult if it is first subjected to short bursts of sublethal ischaemia and reperfusion. The potential of this powerful mechanism has been realised in many branches of medicine where there is an abundance of ongoing research. However, there has been a notable lack of development of the concept in Orthopaedic surgery. The routine use of tourniquet-controlled limb surgery and traumatic soft tissue damage are just two examples of where IPC could be utilised to beneficial effect in Orthopaedic surgery. Methods. We conducted a randomized controlled clinical trial looking at the role of a delayed remote IPC stimulus on a cohort of patients undergoing a total knee arthroplasty (TKA). We measured the effect of IPC by analysing gene expression in skeletal muscle samples from these patients. Specifically we looked at the expression of Heat shock protein-90 (HSP-90), Catalase and Cyclo-oxygenase-2 (COX-2) at the start of surgery and at one hour into surgery. Gene analysis was performed using real time polymerase chain reaction amplification. As a second arm to the project we developed an in-vitro model of IPC using a human skeletal muscle cell line. A model was developed, tested and subsequently used to produce a simulated IPC stimulus prior to a simulated ischaemia-reperfusion (IR) injury. The effect of this on cell viability was investigated using crystal violet staining. Results. In the clinical arm of the study 4 patients were randomized to a control group and 4 randomized to IPC. Operative and post-operative periods were without any adverse incident. For each gene in question there was a different pattern in expression. COX-2 showed an initial up-regulation of 1.43 (p=0.83) at the start of surgery and a subsequent down-regulation of 0.07 (p=0.01) at one hour into surgery. Catalase expression was lower than control at the start of surgery (0.62, p= 0.46) and at one hour into surgery (0.5, p=0.1). HSP-90 expression was initially lower than control at the start of surgery (0.59, p= 0.07) then up-regulated at one hour into surgery (1.13, p=0.62). In the in-vitro section of the study we found that 15 hours of simulated ischaemia was required for a cell death of approximately 50 % (p=0.00001). The introduction of a simulated IPC stimulus increased cell death at a 1 hour reperfusion time-point (IPC group had 18% more cell death than IR group, p=0.003) and at a 24 hour reperfusion time-point (IPC group had 19% more cell death than IR group, p= 0.00001). At a 72 hours reperfusion time-point the IPC group had a 30% greater survival than the IR group (p=0.000006). Conclusion. Our clinical study was subject to small sample size. Despite this it suggests a particular importance of COX-2 in the IPC mechanism. The in-vitro model we developed is an essential resource for further studies into IPC in Orthopaedic Surgery. Preliminary results from this model point towards the ‘second window of protection’ of IPC as a stronger phenomenon than immediate preconditioning